Key Quantitative Figures (Q1 FY27 Ended June 30, 2026)

Financial Performance (Standalone, in ₹ million, unless stated):

  • Total Income: ₹3,083.50
  • Total Expenses: ₹2,024.04
  • Cost of Materials Consumed: ₹1,788.78
  • Decrease in Inventories: ₹(417.67)
  • Employee Benefits Expense: ₹201.17
  • Finance Costs: ₹6.60
  • Depreciation and Amortisation: ₹67.06
  • Other Expenses: ₹378.10
  • Profit Before Tax: ₹1,059.46
  • Total Tax Expense: ₹276.82
  • Current Tax: ₹265.00
  • Short/(Excess) Tax Provision (prior years): ₹11.82
  • Profit for the Period (Net Profit): ₹782.64
  • Earnings Per Share (EPS) (Face Value ₹2): Basic & Diluted: ₹4.51
  • Paid-up Equity Share Capital: ₹346.93 million
  • Other Equity: ₹13,252.19 million

Comparative Figures:

  • Total Income for Q1 FY26 (June 30, 2025): ₹2,575.88 million
  • Net Profit for Q1 FY26: ₹643.44 million
  • EPS for Q1 FY26: ₹3.71

Dates of Action

  • Board Meeting Date: August 03, 2026 (commenced 12:10 PM, concluded 12:27 PM)
  • Dividend Record Date: September 14, 2026
  • 58th AGM Date: September 21, 2026 (11:00 AM IST, via VC/OAVM)

Parties Involved

  • Statutory Auditor: M/s KKC & Associates LLP, Chartered Accountants (Firm Reg. No.: 105146W/W100621)
  • Reviewing Partner: Kamlesh R Jagetia (ICAI Membership No.: 139585)
  • Company Secretary & Compliance Officer: Sweta Poddar (Mem. No. F12287)

Board Approvals and Rationale

1. Unaudited Standalone Financial Results: The Board approved the results for the quarter ended June 30, 2026, which were reviewed by the Audit Committee and the Statutory Auditor.

2. Re-appointment of Executive Chairman: Re-appointed Mr. Akshay B Arora (DIN: 00105637) as Whole Time Director and Executive Chairman for a five-year term from April 13, 2027, to April 12, 2032 (liable to retire by rotation), subject to shareholder approval. Rationale: He is a promoter with over four decades of experience and holds MSc in Organic Chemistry.

3. Re-appointment of Managing Director: Re-appointed Mr. Shiven Akshay Arora (DIN: 07351133) as Managing Director for a five-year term from April 13, 2027, to April 12, 2032 (not liable to retire by rotation), subject to shareholder approval. Rationale: He is a promoter with over ten years of experience and holds a bachelor's degree in business.

4. Re-appointment of Statutory Auditors: Re-appointed M/s KKC & Associates LLP for a second term of five years, until the conclusion of the 63rd AGM, subject to shareholder approval. Rationale: Based on Audit Committee recommendations; described as a peer-reviewed firm with nearly 90 years of experience.

5. Dividend Record Date: Fixed the record date for determining entitlement to the dividend of ₹1.2 per share (60% on face value of ₹2) for FY25-26, as recommended by the Board on May 25, 2026.

6. AGM Schedule: The 58th Annual General Meeting is scheduled for September 21, 2026.

Additional Notes from Financial Statements

  • Business Segment: The company is engaged in a single reportable segment: manufacturing of Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, and APIs used in Pharmaceutical and Healthcare products (per IND AS 108).
  • Subsequent Event (Post-Q1): The company allotted 15,810,276 equity shares (face value ₹2) at an issue price of ₹506 per share (including a premium of ₹504) to QIBs, aggregating ₹8,000.00 million, pursuant to a QIP issue. This is disclosed as a subsequent event and is not reflected in the Q1 financials.
  • No Subsidiaries/Associates/JVs: The company does not have any subsidiaries, associates, or joint ventures, making consolidated financial statements not applicable.

#Tags: #BlueJetHealthcare #Q1Results #Dividend #BoardReappointment #SEBIDisclosure #RegulatoryCompliance #FinancialUpdate #Neutral